GOD Gift Laboratory Private Limited

GOD Gift Laboratory Private Limited is a privately held pharmaceutical company established on November 18, 1992, in Delhi, India. The company is registered under the Corporate Identification Number (CIN) U74899DL1992PTC051019. Its authorized and paid-up capital stands at ₹2.00 crore each. The registered office is located at C-38, 1st Floor, Shivaji Park, Punjabi Bagh, Delhi, 110026.

The company's leadership comprises Directors Pramod Sethi and Manish Kumar. Pramod Sethi has been serving as a director since February 10, 2003, while Manish Kumar joined the board on March 9, 2007. As of the latest available data, GOD Gift Laboratory Private Limited remains an active entity in the pharmaceutical sector.

Specific details regarding the manufacturing facilities of GOD Gift Laboratory Private Limited are not publicly disclosed. The company is known for producing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. However, information about plant locations, capacities, and specializations is not readily available in the public domain.

The key leadership of GOD Gift Laboratory Private Limited includes Directors Pramod Sethi and Manish Kumar. Pramod Sethi has been serving as a director since February 10, 2003, and Manish Kumar joined the board on March 9, 2007. Detailed information about other executive roles, such as CEO, CFO, or other key management personnel, is not publicly available.

GOD Gift Laboratory Private Limited's export data indicates shipments to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's total export value is $193,000 USD, with 10 shipments across two therapeutic categories. The top five products exported are Ceftazidime ($152,000) and Crocin ($41,000), with Crocin holding a 48.7% market share. However, specific regulatory filings, approvals, and market access statuses in these regions are not publicly disclosed.

GOD Gift Laboratory Private Limited's export data does not provide specific information regarding its presence in emerging markets such as Africa, Latin America, or Southeast Asia. The company's export activities are primarily focused on advanced antibiotics and brand-name over-the-counter (OTC) products. Without detailed data, it is challenging to assess the company's penetration in these regions or its compliance with WHO prequalification standards.

The company's export portfolio is concentrated, with the top five products accounting for 100% of the export value. This indicates a lack of diversification in its product offerings. While the company holds a leading position in the Crocin market, the heavy reliance on a limited product range may expose it to risks associated with market fluctuations and regulatory changes. A more diversified product portfolio could mitigate such risks and enhance the company's strategic position.

Specific information regarding GOD Gift Laboratory Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not provide insights into its compliance with FDA regulations or its standing in the U.S. market. Without such information, it is difficult to assess the company's regulatory status and market access in the United States.

There is no publicly available information regarding GOD Gift Laboratory Private Limited's compliance with World Health Organization (WHO) prequalification standards or possession of European Union Good Manufacturing Practice (EU GMP) certificates. The company's export data does not indicate adherence to these international quality standards, which are crucial for market access in various regions. Without such certifications, the company's ability to compete in regulated markets may be limited.

Specific details about GOD Gift Laboratory Private Limited's compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data does not provide insights into its adherence to Indian regulatory standards, which are essential for domestic and international operations. Without such information, it is challenging to assess the company's regulatory standing within India.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to GOD Gift Laboratory Private Limited. The company's export data does not indicate any recent regulatory actions or compliance issues. However, the absence of such information does not necessarily confirm the company's compliance status, as regulatory actions may not always be publicly disclosed.

GOD Gift Laboratory Private Limited operates in the pharmaceutical sector, exporting products such as Ceftazidime and Crocin. The company's export data indicates that Crocin holds a 48.7% market share, suggesting a leading position in this product category. However, without specific information about competitors in overlapping categories, market share comparisons, and head-to-head analyses, it is difficult to assess the company's competitive standing. The lack of diversification in the product portfolio may also impact its ability to compete effectively in the market.

GOD Gift Laboratory Private Limited's key differentiator lies in its leading position in the Crocin market, with a 48.7% market share. This indicates strong brand recognition and consumer trust in this product. However, the company's heavy reliance on a limited product range may limit its ability to leverage other potential differentiators and competitive advantages. Diversifying the product portfolio could enhance the company's market position and appeal to a broader customer base.

GOD Gift Laboratory Private Limited's current strategic direction appears to be focused on the export of finished pharmaceutical formulations, particularly in the categories of advanced antibiotics and brand-name OTC products. The company's export data indicates a concentration in these areas, with the top five products accounting for 100% of the export value. The heavy reliance on a limited product range may expose the company to risks associated with market fluctuations and regulatory changes. A more diversified product portfolio and strategic focus on emerging markets could enhance the company's resilience and growth prospects.

GOD Gift Laboratory Private Limited's export data indicates a total export value of $193,000 USD across 10 shipments, with a portfolio concentration of 100% in the top five products. This suggests a consistent export volume, albeit limited in scope. The company's reliance on a narrow product range may impact its ability to establish a broader and more reliable supply chain. Enhancing product diversification and exploring new market opportunities could improve the company's supplier assessment and overall business performance.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

• WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practice (WHO-GMP) standards. Verification can be done by reviewing the company's certifications or contacting the World Health Organization.

• EU GMP Certification: Check for compliance with European Union Good Manufacturing Practice (EU GMP) standards. This can be verified through the European Medicines Agency (EMA) or by contacting the company.

• ISO Certification: Verify that the company holds relevant International Organization for Standardization (ISO) certifications, such as ISO 9001 for quality management systems. This information can typically be found on the company's official website or by contacting them directly.

Importers should undertake the following steps to ensure due diligence:

• Verify Regulatory Approvals: Confirm that the company's products have the necessary approvals from relevant regulatory bodies, such as the FDA, WHO, and EU authorities.

• Assess Manufacturing Facilities: Evaluate the company's manufacturing facilities for compliance with international quality standards, including WHO-GMP and EU GMP.

• Review Financial Stability: Examine the company's financial statements to assess its financial health and stability.

• Check for Legal Compliance: Ensure that the company complies with all applicable laws and regulations in its operating regions.

• Evaluate Product Quality: Request samples and conduct quality assessments to ensure that the products meet the required standards.

• Monitor for Red Flags: Be vigilant for any signs of financial distress, legal issues, or quality concerns that may indicate potential risks.

By following this checklist, importers can make informed decisions and establish reliable partnerships with GOD Gift